Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
CD47 Inhibitor Market : Competitive Landscape, Pipeline, and Market Analysis 2023
CD47 Inhibitor Market : Competitive Landscape, Pipeline, and Market Analysis 2023
CD47 (Cluster of Differentiation 47) also known as integrin-associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene. CD47 belongs to the immunoglobulin superfamily and partners with membrane integrins and also binds the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRPα). CD47 is involved in a range of cellular processes, including apoptosis, proliferation, adhesion, and migration. Furthermore, it plays a key role in immune and angiogenic responses. CD47 is ubiquitously expressed in human cells and has been found to be overexpressed in many different tumor cells. CD-47 acts as a don't eat me signal to macrophages of the immune system which has made it a potential therapeutic target in some cancers and more recently for the treatment of pulmonary fibrosis. The mechanism of action (MOA) of CD47 Inhibitor is CD47 ligation induces apoptosis of tumor cells through a caspase-independent mechanism. Secondly, anti-CD47 leads to tumor cell phagocytic uptake by antigen-presenting cells and subsequent antigen presentation to T cells. CD47 inhibitors are used in the treatment of lymphoma, acute myelogenous leukemia, adenocarcinoma, carcinoid tumor, cholangiocarcinoma, etc. Increased prevalence of adenocarcinoma and leukemia and increase investment in R&D are the key drivers for the CD47 Inhibitor market. For instance, according to the World Health Organization 2020, there were an estimated 4.3 million cases reported of all types of cancers. The introduction of newer products by market players may look for opportunities that have a big impact on comprehensive research and development in CD47 Inhibitors and to address the difficulties in therapy, numerous market participants are developing innovative compounds. For instance, Gilead’s Magrolimab (GS-4721) for the indication of patients with acute myeloid leukemia is under the various stages of clinical studies.
CD47 Inhibitor Market Key Developments:
In May 2018, Forty Seven Inc’s 5F9 was the first-in-class CD47 monoclonal antibody approved by the Food and Drug Administration (FDA) for the treatment of two types of lymphomas Relapsed-Refractory B-cell non-Hodgkin lymphomas.
Drugs under the Pipeline for CD47 Inhibitor:
Clinical Activity and Developments of CD47 Inhibitor:
|
Molecule Name |
Number of Studies |
|
Magrolimab (GS-4721) |
32 |
|
RRX-001 |
13 |
|
Evorpacept (ALX148) |
13 |
|
Ligufalimab (AK117) |
9 |
|
Maplirpacept (PF-07901801) |
9 |
The molecules such as Magrolimab (GS-4721) under clinical development by Gilead in global collaboration with Ono Pharma for the line of treatment for an acute myeloid leukaemia and myelodysplastic syndromes. Pfizer’s Maplirpacept (PF-07901801) is under development for the indication of acute myeloid leukemia, diffuse large b cell lymphoma, multiple myeloma, ovarian cancer in phase 1 and 2 of clinical trial.
The development of CD47-targeting therapeutics is currently limited to the preclinical and clinical phases. Researchers have created monoclonal antibodies that target CD47 in light of the enormous clinical success of monoclonal antibodies. With a large range of pharmaceutical companies actively engaging in research and development operations linked to this industry, the CD47 inhibitor market is extremely competitive on a global scale. To preserve their position in the worldwide market, the major market players have also embraced strategic alliances such as partnerships, acquisitions, joint ventures, and collaborations. For instance, Actinium Pharmaceuticals entered into research collaboration with EpicentRx to study Actinium's Actimab-A targeted radiotherapy in combination with RRx-001 in 2022. Although the US is one of the key regions that supports research and development efforts linked to CD47 targeting medicines, China has also made significant progress with CD47 inhibitors. Nearly half of the clinical pipeline products worldwide have received NMPA approval for clinical research for more than 17 medications to far. A strong pipeline of CD47 targeting drugs has been developed by local Chinese pharmaceutical companies, including I-Mab BioPharma, Innovent Biologics, ImmuneOnco, Hengrui, Waterstone Hanxbio, and others. These drugs are anticipated to receive regulatory approval soon. According to the report findings, the market for CD47 inhibitors would reach more than US$ 2 billion by 2028. The enormous growth rates in the anticipated period are due to a number of causes, including an increase in pharmaceutical companies' R&D efforts, a rise in cancer prevalence and the resulting demand for targeted therapies, as well as supportive government policies. In the near future, it is anticipated that CD47 inhibitors will account for a sizeable portion of the global market for cancer immunotherapy.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Forty Seven Inc’s 5F9 was the first-in-class CD47 monoclonal antibody approved by the Food and Drug Administration (FDA).
Ono Pharma. Gilead Sciences, EpicentRx,ALX Oncology, Akesobio, Pfizer are few leading market players in CD47 Inhibitor market.
lymphoma, acute myelogenous leukemia, adenocarcinoma, carcinoid tumor, cholangiocarcinoma, etc. are the major indication of CD47 Inhibitor.
There are a total of 46 molecules that are in the Phase-1, Phase-2 and Phase-3 clinical development.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.